BBT-401-1S

· Bridge Biotherapeutics, Inc.

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for BBT-401-1S, covering 2022-03-21 to 2023-09-07. Get the full timeline:

Most recent: Clinical Trial Update: Efficacy and Safety of Orally Administered BBT-401-1S in Subjects With Ulcerative Colitis [Phase 2]